Chee KayCheung University of LeicesterUnited Kingdom

Chee KayCheung
Dr. Chee Kay Cheung is a Consultant Nephrologist and Honorary Associate Professor, University of Leicester, UK. His PhD examined factors that contribute towards progressive kidney damage in IgA nephropathy, and current interests are in clinical trials in glomerular diseases, especially in IgAN. He leads a number of investigator-initiated studies in this area in collaboration with pharmaceutical companies and academic partners, and has served as UK national chief investigator and principal investigator on multiple clinical trials. He leads specialist clinics in glomerular diseases and in vasculitis and lupus nephritis. He is a steering committee member and active member of several national working groups, including the UK glomerular diseases clinical studies group and UK IgAN and membranous nephropathy rare disease groups.
Institution

Day 1 - Sunday April 14, 2024

Time Session
9 a.m.
10:30 a.m.
Precise Phenotyping and Treatment
HeatherReich Chairperson Heather.Reich@uhn.caUniversity of Toronto, University Health NetworkCanada
SebastiánJaurretche Chairperson sebastianjaurretche@hotmail.comSanatorio Parque SAArgentina
  • Deciphering the IGAN Cell Atlas
    JulioSaez-Rodriguez Speaker julio.saez@uni-heidelberg.deHeidelberg UniversityGermany
  • Complement-mediated Kidney Diseases in the Era of Complement Inhibitors
    MarinaVivarelli Speaker marina.vivarelli@opbg.netLaboratory of Nephrology, Bambino Gesù Children's HospitalItaly
  • CART-T Cell for Refractory Lupus
    JonathanHogan Speaker jonathan.hogan@cabalettabio.comCabaletta Bio
  • New Targets to Reduce the Burden of Rare Kidney Diseases
    LauraMariani Speaker lmariani@umich.eduUniversity of MichiganUnited States
  • Q and A
Hall C4
10:30 a.m.
11 a.m.
Hitting the Four Hits: The Potential of Dual BAFF/APRIL Inhibition in IgA Nephropathy
JonathanBarratt Spotlight Speaker jb81@leicester.ac.ukUniversity of Leicester, Leicester, UKUnited Kingdom
Spotlight Stage 1 (exhibition hall)

Day 2 - Monday April 15, 2024

Time Session
12:45 p.m.
1:30 p.m.
Keys to success to be on top of what is published in nephrology (ISN-ACT)
AndreaViecelli Spotlight Speaker andrea.viecelli@health.qld.gov.auUniversity of QueenslandAustralia
Augusto CesarSoares Dos Santos Junior Spotlight Speaker acssjunior@hotmail.comHospital das Clinicas, UFMG; Fac Ciências MedicasBrazil
BrendanSmyth Spotlight Speaker brendan.smyth@sydney.edu.auAustralia
DavidWheeler Spotlight Speaker d.wheeler@ucl.ac.ukUniversity College LondonUnited Kingdom
MegJardine Spotlight Chairperson meg.jardine@sydney.edu.auNHMRC Clinical Trials Centre, University of Sydney, AustraliaAustralia
Spotlight Stage 1 (exhibition hall)
3 p.m.
4 p.m.
Late Breaking Clinical Trials Session
AlessiaFornoni Chairperson afornoni@med.miami.eduUnited States
MichelleRheault Chairperson rheau002@umn.eduUniversity of MinnesotaUnited States
  • Predicting the Risks of Kidney Failure and Death in Adults With Moderate-to-severe Chronic Kidney Disease (KDpredict)
    PietroRavani Free Communication pravani@ucalgary.caUniversity of CalgaryCanada
  • Plasma Exchange in ANCA Associated Vasculitis GN: Update After Pexivas – Recommendations and Updates
    Wladimir MietekSzpirt Speaker wladimir.mietek.szpirt.01@regionh.dkRigshospitalet, University of Copenhagen, Dept. of Nephrology, Denmark, Senior Research ConsultantDenmark
  • EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
    DanaRizk Free Communication drizk@uabmc.eduUniversity of Alabama at BirminghamUnited States
  • SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
    JonathanBarratt Free Communication jb81@leicester.ac.ukUniversity of Leicester, Leicester, UKUnited Kingdom
  • PREGNANCY AMONG WOMEN ON CHRONIC DIALYSIS : THE FRENCH COHORT
    CécileCouchoud Free Communication cecile.couchoud@biomedecine.frREIN registry, Agence de la biomédecine, FranceFrance
Hall A
4:30 p.m.
5:30 p.m.
Designing Smart Clinical Trials
DebbieGipson Chairperson debbie.gipson@nih.govNational Institutes of Health/NIDDKUnited States
JonathanBarratt Chairperson jb81@leicester.ac.ukUniversity of Leicester, Leicester, UKUnited Kingdom
  • Patients Subphenotyping: The Example of Diabetic Kidney Disease
    John CijiangHe Speaker cijiang.he@mssm.eduIcahn School of Medicine at Mount SinaiUnited States
  • Power of AI to Develop Data-driven Early Detection, Diagnosis, and Management of Kidney Disease
    LauraMariani Speaker lmariani@umich.eduUniversity of MichiganUnited States
  • Targeted Approaches in Clinical Trial Design
    HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
  • Q and A
Hall D

Pre-Congress - Saturday April 13, 2024

Time Session
11:30 a.m.
1:30 p.m.
Primer Course in Glomerular Disease: A Case-Based Approach: Nephrotic Syndrome
AdrianLiew Chairperson draliew2@gmail.comMount Elizabeth Novena Hospital, SingaporeSingapore
HeatherReich Chairperson Heather.Reich@uhn.caUniversity of Toronto, University Health NetworkCanada
HernánTrimarchi Chairperson htrimarchi@hotmail.comHOSPITAL BRITÁNICO DE BUENOS AIRESArgentina
JonathanBarratt Chairperson jb81@leicester.ac.ukUniversity of Leicester, Leicester, UKUnited Kingdom
  • Approach to Nephrotic Syndrome
    Chee KayCheung Speaker ckc15@leicester.ac.ukUniversity of LeicesterUnited Kingdom
  • Case Presentation and Discussion 2
    MarinaVivarelli Speaker marina.vivarelli@opbg.netLaboratory of Nephrology, Bambino Gesù Children's HospitalItaly
  • Case Presentation and Discussion 3
    KeishaGibson Speaker keisha_gibson@med.unc.eduUniversity of North Carolina at Chapel Hill, USAUnited States
  • Case Presentation and Discussion 4
    HeatherReich Speaker Heather.Reich@uhn.caUniversity of Toronto, University Health NetworkCanada
Hall E